Veerhealth Care Reports Strong FY26 Performance with 86.08% YoY Growth in EBITDA and 33.29 Crore in Total Revenues

Veerhealth Care Reports Strong FY26 Performance with 86.08% YoY Growth in EBITDA and 33.29 Crore in Total Revenues​

Mumbai, June 1, 2026: Veerhealth Care Limited, specializing in ayurvedic medicines and oral care products through its brand Ayuveer, has reported robust financial results for the year and quarter ended March 31, 2026. The company achieved an 86.08% year over year (YoY) growth in EBITDA, reaching 3.27 Crore, while recording Total Revenues of 33.29 Crore, marking a 6.08% YoY growth.

Veerhealth Care Limited, which focuses on delivering safe and affordable daily care experiences using natural ingredients, highlighted strong growth driven by expanding international and domestic market footprints.

Financial Performance Snapshot (FY26 Standalone)​

The company’s financial performance for the fiscal year 2026 demonstrated significant growth in key operational metrics.


The report noted that the Net Profit or 0.54 Crore saw a 38.16% YoY growth. However, the Q4 FY26 Profit was impacted due to a Loss on 0.31 Crore, classified as Exceptional items, and a Provision of 0.49 Crore for Deferred Tax.

Strategic Market Milestones and Global Expansion​

The company highlighted several factors boosting its market position, noting that the India-EU Trade Deal 2026 is transforming the future of Modern Ayurveda exports. This deal is reported to be opening new growth opportunities in the global wellness market by facilitating reduced tariffs, improved regulatory access, and increased European demand for natural healthcare products.

In line with its "Local to Global" ambition, Veerhealth Care is actively focusing on scaling its manufacturing and export operations for products within the medical device category in the U.S. market. Additionally, discussions are ongoing with a major Russian group concerning oral care exports, with expected entry into the Russian market soon.

During the first half of FY26, the company secured key milestones, including:

• USA Export Orders: Approximately 19 crores.
• Domestic Market Presence: 0.28 crores.
• Domestic Pharmacy Chain Reach: Approximately 1.7 thousand.
• Leading FMCG Company Market Share: Approximately 0.08 crores.
• E-commerce Expansion: Successfully onboarded Ayuveer products on Myntra, expanding presence across Amazon, Flipkart, Nykaa, Glowroad, Jiomart, and Myntra.
• Manufacturing: Commenced production at a new facility equipped with in-house plastic molding and packaging, and board integration capabilities.

Furthermore, the company noted that globally, few small-cap companies have secured USFDA plant clearance, positioning Veerhealth Care in a distinctive category.

Future Outlook and Management Commentary​

In terms of future projections, the company anticipates total revenues of 70-75 crores and a PAT of 7-10% in FY27. Furthermore, Veerhealth Care aims to achieve revenues of approximately 100 crores with a PAT of 10% within the next 24 months.

Commenting on the financial performance, Bhavin Shah, Managing Director of Veerhealth Care Limited, stated that the company is delighted with the strides made in FY26, reporting its highest ever Total Revenues of 33.29 crore. He attributed the growth to the consistent focus on expanding the international footprint and strengthening the domestic presence. Mr. Shah added that the growth in export sales and the addition of new product categories have significantly bolstered the company’s position in both global and local markets, and existing order book levels are expected to sustain high growth rates in the coming quarters.

Stock Price Movement​

Veerhealth Care Ltd settled at ₹24.56 today, marking a solid gain of +0.24% for the shares. The stock traded within a range on Tuesday, testing a low of ₹23.76 before hitting an intraday high of ₹24.94.